Critical Appraisal


Dr. Nada A. Al-Yousefi

Assistant Professor and Consultant Family Medicine Unit Department of Family and Community Medicine College of Medicine(KSU) nalyousefi@ksu.edu.sa Feb 18, 2016



Objectives of the lecture:

- Show how to do critical appraisal and check the appropriateness of study design for the research question.
- Learn how to do careful assessment of the key methodological features of the research design.
- Learn how to check the potential conflicts of interest.
- Learn how to examine the suitability of the statistical methods used and their subsequent interpretation.
- Explain the implications of research findings for individual patients, elicit patients' own preferences and develop an appropriate management plan based on the combination of this information.



What's A Paper on Therapy?

Clinical Trial (Controlled) Compares

INTERVENTION with CONTROL

Clinical Trial Compares – INTERVENTION


- Drug (New)
- Structured exercise program (e.g. osteoporosis)
- Surgical procedure

- CONTROL

- Placebo, old drug or old intervention
- Usual regular advise given (osteoporosis)
- Another surgical procedure / No surgery

Process of RCTs

- Preparation: Randomization, Computer generated list
- Eligibility assessment (Inclusion/exclusion)
- ✓ Consent
- ✓ Allocation to study arms (Concealment)
- ✓ Baseline assessment
- ✓ Initiation of intervention (Blind)
- ✓ Follow-up
- ✓ Outcome assessment
- ✓ Data analysis



Appraise the Evidence

- Assess validity? Correctness (likely to be true)
- What are the **results**? Clinically important
- Can we **apply** the results to our patient?
 Applicable in and useful for my patients

Users' Guides to the Medical Literature

A Manual for Evidence-Based Clinical Practice

The Evidence-Based Medicine Working Group

Edited by Gordon Guyatt, MD Drummond Rennie, MD Robert Hayward, MD (interactive guides)





APPLICABILITY



SULTS

VALIDITY

- ≻Randomization.
- ≻Concealment.
- ≻Blindness.
- ≻Follow up complete.
- >Intention to treat.
- ≻Similar groups at start.
- ≻Both groups treated equally.


Randomization

- Randomisation = similar groups at baseline
 Equal (50%) chance to be in either group
 How was it randomized?
- >Was randomization concealed?
 - selection
 - allocation

concealed allocation

Did investigators know to which group the potential subject would be assigned before enrolling them?

Trials with unconcealed allocation consistently overestimate benefit by ~40%



Selection bias

Reduced by:

- centralised randomisation
- on-site computer system with group assignments in a locked file
- sequentially numbered, sealed, opaque envelopes
- × Not: alternation, dates of birth, day of week.


Blindness >Who is Blind?

Physicians-Nurses-Patients-Data gathering staff- data analyzers.

- Single, double...

Blindness

- If patient knows: *Placebo effect* Those who are on effective treatment perform better than those who receive Placebo
- If Physician knows: *Overestimate Treatment effect* (More care, Cointervention)






• duration of study.


• **drop out < 20%**.

INTENTION TO TREAT

All patients analyzed in the groups to which they were allocated

INTENTION TO TREAT (ITT)





How RCTs differ from other designs

Two balanced groups:

- **Start Balanced:** All prognostic factors are equally distributed at the start (Concealed Randomization)
- **Run Balanced:** All prognostic factors are maintained balanced throughout the study (Blindness and the 3C)
- End Balanced: All prognostic factors are maintained balanced at the end of the study (ITT)



Figure 1. Profile of the Estrogen Plus Progestin Component of the Women's Health Initiative





Figure 1. Flowchart of Patient Disposition at 6 Months



Menerba® Phase 3 Advanced Clinical Trial Design


PI: Wulf Utian, M.D., Ph.D. D.Sc.


Founder and President Emeritus of the North American Menopause Society (NAMS)

40 U.S. Clinical Sites Approved and Trained

Eligibility:

- Postmenopausal women ages 40-65
- ≥ 7 moderate to severe hot flashes/day







"The police called, we're taking you out of the clinical trial and putting you in a criminal trial."

WHAT DO WE LOOK FOR?

• VALIDITY

• IMPORTANCE

• APPLICATION

VALIDITY

Are the results of this single preventive or therapeutic trial valid?

Was the assignment of patients to treatments randomised?

Was the randomisation list concealed?

Was follow-up of patients sufficiently long and complete?

Were all patients analysed in the groups to which they were randomised?

Were patients and clinicians kept "blind" to treatment?

Were the groups treated equally, apart from the experimental treatment?

Were the groups similar at the start of the trial?

Was the assignment of patients to treatments randomised?

Was the randomisation list concealed?

Ensuring Allocation Concealment

BEST – most valid technique

Central computer randomization




Envelopes, etc





NOT RANDOMIZED Date of birth, alternate days, etc

Was follow-up of patients sufficiently long and complete?




EER= 270/? CER=130/?

Losses-to-follow-up How many is too many?

"5-and-20 rule of thumb"

5% probably leads to little bias>20% poses serious threats to validity

Were all patients analysed in the groups to which they were randomised?



EER= 270/? CER=130/?

Intention-to-Treat Principle Maintaining the randomization

Principle:

Once a patient is randomized, s/he should be analyzed in the group randomized to - even if they discontinue, never receive treatment, or crossover.

Exception: If patient is found on BLIND reassessment to be ineligible based on pre-randomization criteria.

Were patients and clinicians kept "blind" to treatment?

Measurement Bias minimizing differential

- Blinding Who?
 - Participants?
 - Investigators?
 - Outcome assessors?
 - Analysts?
- Most important to use "blinded" outcome assessors when outcome is not objective!
- Papers should report WHO was blinded and HOW it was done



Figure 1: The authors: double blinded versus single blinded



Figure 2: The authors blinded and masked


Schulz and Grimes. Lancet, 2002

Best RCTs: Double Blind

- Subject doesn't know which he's getting.
- Researcher doesn't know which he's giving.



 Exit poll to see if patients could guess if they were in the placebo group



Were the groups treated equally, apart from the experimental treatment?

Were the groups similar at the start of the trial?

IMPORTANCE


MEASURES OF ASSOCIATION

Definition

• Number Needed to Treat (NNT):

 Number of persons who would have to receive an intervention for 1 to benefit.

NNT=1/ARR



EER= 270/? CER=130/?

EER=270/1000=27%=0.27 CEER=130/1000=13%=0.13 ARR=0.27-0.13=0.14 NNT=1/0.14=7



NUMBER NEED TO HARM(NNH)

WHAEN THE OUTCOME IS UNFAVOURABLE

Therapy

ARR
RR
RRR
NNT
CI

Result

- Result Experimental Event Rate (EER) Risk (or chance) of outcome event in experimental group
- Results control event rate (CER) Risk (or chance) of outcome event in control group.

Result

<u>Relative Risk (RR)</u>

• A measure of the chance of the event occurring in the experimental group relative to it occurring in the control group.

• $\mathbf{RR} = \mathbf{EER} / \mathbf{CER}$

Relative Risk Reduction (RRR):

• RRR=CER-EER/CER

• A RRR of 25% means that the new treatment reduced the risk of death by 25% relative to that occurring among control patients; the greater the relative risk reduction, the more effective the therapy.

Absolute Risk Reduction (ARR)

- The absolute difference between the risk of the event in the control and experimental groups.
- ARR = CER EER

Number needed to treat (NNT)

- Measure of clinical significance
- How many pat's have to be treated with intervention in order one patient Would expected to benefit.

• NNT=1/ARR

Conversely, can do number needed to harm
uses harmful outcomes, eg death, weight gain

Magnitude (treatment effect):

- Absolute effects (ARR & NNT)
- Relative effects (RR, RRR)

Precision:

o**P value.**

• Confidence interval?

Result Tabulation

	Event + Ve	Event - Ve	Total
Experimental	۵	b	a+b
Control	С	d	c+d

- EER = Experimental Event Rate (a/a+b)
 - CER = Control Event Rate (c/c+d) •

Result Tabulation				
	Bleeding	Bleeding	Total	
	present	Absent		
Drug A	20	80	100	
Drug B	40	60	100	

- EER-A (Risk A) = 20/100 = 20% (0.2) •
- CER-B (Risk B) = 40/100 = 40% (0.4) •



> ARR = CER - EER

> NNT = 1 / ARR

> RR = EER/CER (Risk A/Risk B)

> RRR = 1 - RR

Result Tabulation

	Bleeding	Bleeding	Total
	present	Absent	
Drug A	20	80	100
Drug B	40	60	100

 $ARR = CER - EER \qquad NNT = 1 / ARR \bullet$

 $RR = EER/CER \qquad \qquad RRR = 1 - RR \bullet$

Calculations

► ARR = CER - EER = 0.4 - 0.2 = 0.2 (20%)

5

0.5

- ► NNT = 1 / ARR = 1/0.2 =
- ► RR = EER/CER = 0.2/0.4 =
- ► RRR = 1- RR = 1- 0.5 = 0.5 (50%)

Confidence intervals?

- The range within which the likelihood of a true value is expected to be within a given degree of certainty, usually evaluated at 95% CI.
- Precision


Confidence Intervals (Estimation) in DVT study

- Incidence of DVT
 - Stocking group O
 - No Stocking group 0.12



Risk difference = 0.12 - 0 = 0.12(95% CI, 0.058 - 0.20) The true value could be as low as 0.058 or as high as 0.20 - but is probably closer to 0.12

Since the CI does not include the 'no effect' value of '0' → the result is statistically significant



APPLICABILITY

CAN I APPLY THESE VALID, IMPORTANT RESULTS TO MY PATIENT?

- Do these results apply to my patient?
 - IS OUR PATIENT SO DIFFERENT?
 - IS THE TREATMENT FEASIBLE?
 - POTENTIAL BENEFITS AND HARMS

 Are my patient's values and preferences satisfied by the intervention offered?

Summary

- Validity is the paper likely to be true
- Importance size of effect
 NNT
 Percision
- Applicability can it work for me/my setting



http://www.ebm.med.ualberta.ca/Therapy.html

Evidence Based Medicine				
Toolkit				
Home		Home>Domains-Therapy/Prevention-Appraisal Guide		
About EBM	۲	Therapy/Prevention Article		
Domains	۲	Appraisal Guide		
Practice Guidelines	۲			
Systematic Review	×	Questions to Ask Yourself		
Economic Analysis	۲	Are the results <u>valid</u> ?		
Glossaries	۲	1. Was the assignment of patients to treatment <u>randomized</u> ?		
JAMA User's Guide				
Links	•	2. Were all patients who entered the trial properly accounted for and attributed at its conclusion?		
		Was <u>follow-up</u> complete? Were patients analyzed in the groups to which they were randomized ? Intention to treat analysis?		



Take-home messages:

- Different types of question require different study designs.
- Does the study address a <u>clearly focused</u> <u>question</u>?
- Did the study use valid methods to address this question?
- Are the valid results of this study important?
- Are these valid, important results applicable to my patient or population?

Refrences

- Critical Appraisal tools and Work sheets
 <u>http://www.cebm.net/critical-appraisal/</u>
- Jane M Young & Michael J Solomo. How to critically appraise an article. Nature Reviews Gastroenterology and Hepatology 6, 82-91 (February 2009) | doi:10.1038/ncpgasthep1331
- What is a critical appraisal? <u>http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis</u> <u>/what_is_critical_appraisal.pdf</u>
- The BMJ How to Read a Paper <u>http://www.bmj.com/about-bmj/resources-readers/publications/how-read-paper</u>
- Evidently Cochrane <u>http://www.evidentlycochrane.net/</u>
- CEBM <u>http://www.cebm.net/</u>

